BioCentury | Apr 9, 2020
Product Development

April 8 COVID-19 roundup: National Academy of Sciences says COVID-19 could continue through summer; plus HHS, SAb-CSL, Vanda-UIC, Avacta-Cytiva and more

As companies and academic groups continue to form new partnerships and identify new drug targets to combat COVID-19, a National Academy of Sciences committee has warned there’s no guarantee the pandemic will be completely contained...
BioCentury | Jan 10, 2020
Product Development

Seeking structural endpoints for OA

...a secondary endpoint in its Phase IIa study of MIV-711. The low dose of the CTSK...
...ADAM metallopeptidase with thrombospondin type 1 motif 5 CLK-2 - CDC-like kinase 2 CTSK - Cathepsin K...
BioCentury | Jan 9, 2020
Targets & Mechanisms

Cancer's trajectory, as viewed by targets at AACR, ASCO and ASH

Beyond the headliner presentations at 2019’s three major cancer conferences were over a hundred posters and presentations showcasing new or emerging targets. A look at the identity of those targets reveals the growing diversity of...
BioCentury | Aug 23, 2019
Targets & Mechanisms

New targets in osteoarthritis are about more than just pain

...AB’s Phase II candidate MIV-711 also is designed to prevent enzymatic cartilage degradation, by blocking cathepsin K...
...1 motif 5 ADORA3 - Adenosine A3 receptor BMP7 (OP-1) - Bone morphogenic protein 7 Cathepsin K (CTSK)...
BioCentury | Jan 24, 2018
Emerging Company Profile

D over L for diabetes

ImmunoMolecular Therapeutics LLC’s small molecule inhibitor of an HLA-DQ8 peptide could treat Type I diabetes without courting the broad-spectrum immunosuppression of other disease-modifying therapies in development. About 60% of Type I diabetes patients carry the...
BioCentury | Dec 8, 2017
Financial News

Lumicell raises $28.7M series C, reports breast cancer detection data

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million on Dec. 7 in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed...
BioCentury | Dec 8, 2017
Product Development

Making of Mepsevii

It may take a few years for Ultragenyx Pharmaceutical Inc. to recoup its investment in Mepsevii vestronidase alfa-vjbk, but the company expects to continue to reliably churn out treatments for ultra-rare diseases alongside a portfolio...
BioCentury | Dec 7, 2017
Financial News

Lumicell raises $28.7M series C, reports breast cancer detection data

Cancer imaging company Lumicell Inc. (Wellesley, Mass.) raised $28.7 million in a series C round led by new investors Launch Capital and BlueIO. Existing investor Kodiak also participated, as did other undisclosed investors. Lumicell said...
BioCentury | Oct 10, 2017
Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling A panel of 17 genomic loci could help predict the risk of PD. Genome-wide association studies in a total of 20,084 PD patients and 397,324 healthy volunteers identified associations between the disease...
BioCentury | Sep 29, 2017
Clinical News

Medivir reports Phase IIa data of MIV-711 for OA

...now plans to seek a partner to further develop the reversible small molecule inhibitor of cathepsin K (CTSK)...
...Stockholm, Sweden Product: MIV-711 Business: Autoimmune Molecular target: Cathepsin K (CTSK) Description: Reversible small molecule inhibitor of CTSK...
...and femoral cartilage thickness Status: Phase IIa data Milestone: Additional Phase IIa data (1Q18) Chris Lieu MIV-711 Medivir AB Cathepsin K (CTSK)...
Items per page:
1 - 10 of 170